$BBIO SEC Filings

Filed On	Filing
13 Oct 2026	8-K: Other Events - Accepted for Priority Review with a PDUFA target action date of February 4, 2027; being granted Priority Review by the FDA underscores the significant unmet need for an oral targeted therapeutic option for children with achondroplasia
21 Sep 2026	Form 4: Kumar Neil, Director Sold 10,000 shares ($691K)
31 Aug 2026	8-K: Other Events
20 Aug 2026	Form 4: Kumar Neil, Director Sold 34,980 shares ($2.89M) · Sold 10,000 shares ($840K)
19 Aug 2026	144
18 Aug 2026	Form 4: Trimarchi Thomas, President and CFO Gave up 22,781 shares to cover exercise price or tax ($1.82M)
18 Aug 2026	Form 4: Kumar Neil, Director Received 71,217 shares by exercise or conversion · Gave up 36,237 shares to cover exercise price or tax ($2.89M)
18 Aug 2026	Form 4: Apuli Maricel, Chief Accounting Officer Gave up 4,714 shares to cover exercise price or tax ($376K)
18 Aug 2026	144
17 Aug 2026	SCHEDULE 13D/A
17 Aug 2026	144
17 Aug 2026	8-K: Entry into a Material Definitive Agreement; Other Events
14 Aug 2026	424B7
10 Aug 2026	10-Q
10 Aug 2026	8-K: Results of Operations and Financial Condition
03 Aug 2026	Form 4: Apuli Maricel, Chief Accounting Officer Sold 2,000 shares ($160K)
03 Aug 2026	SCHEDULE 13G/A
27 Jul 2026	SCHEDULE 13G/A
24 Jul 2026	S-8
24 Jul 2026	S-3ASR

Comments